Asuragen said this week that it has taken a non-exclusive license to the BRAF V600E mutation from Johns Hopkins University for use in its CLIA laboratory for clinical research and patient testing for a range of cancers.

The presence of the V600E mutation in the BRAF oncogene has been shown to impact prognosis and the prediction of therapeutic response in colorectal cancer and also predicts a poorer prognosis in thyroid cancer, Asuragen said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.